Unique Effects of Clozapine: A Pharmacological Perspective
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Schizophrenia is a heterogenous and severe neuropsychiatric disorder that affects nearly 1% of the population worldwide. Antipsychotic drugs are the mainstay of treatment, but not all patients with schizophrenia respond to treatment with these agents. Clozapine, the first atypical antipsychotic, is a highly effective medication for patients with schizophrenia who do not respond to other antipsychotics. Although clozapine tends not to produce extrapyramidal symptoms, other side effects of the drug (e.g., agranulocytosis, myocarditis, seizures) limit its widespread use. This chapter reviews clozapine’s unique clinical effects and unusual pharmacological profile. In addition to its effects in treatment resistant schizophrenia, clozapine has been shown to decrease suicidality, which occurs at an increased rate in patients with schizophrenia. Still preliminary, but consistent data, also suggest that clozapine limits substance use in these patients, an important effect since substance use disorders are common in patients with schizophrenia and are associated with a poor outcome, including an increased risk for suicide and poor response to treatment. We have suggested, from animal studies, that clozapine’s apparent ability to limit substance use may occur through its actions as a weak dopamine D2 receptor antagonist, a potent norepinephrine ɑ-2 receptor antagonist and a norepinephrine reuptake inhibitor. Using animal models, we have built combination of agents toward creation of safer clozapine-like drugs to reduce substance use in these patients. Future research into the mechanisms of action of clozapine toward the development of safe clozapine-like agents is of great public health importance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
The Self-Medication Hypothesis of Substance Use Disorders: A Reconsideration and Recent Applications
Khantzian, E. J. (1997) · Harvard Review of Psychiatry · doi:10.3109/10673229709030550 · Cited by 3,242 · cited 2×
“…use of alcohol and other substances in patients with schizophrenia invokes the “self-medication hypothesis”, where the alcohol/substance abuse relates to an attempt by the patient to self-medicate negative symptoms or the extrapyramidal side effects of antipsychotics (Khantzian, 1997; Siris, 1990).”
BackgroundDopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Grace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 1×
“…with schizophrenia are at a significantly high risk for suicide, as approximately 50% of patients attempt suicide, compared to only 1% in the general population, and 10% of patients with schizophrenia die from suicide (Meltzer et al., 2003; Meltzer & Baldessarini, 2003).”
BackgroundNMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Co‐Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders
Kalman, D., Morissette, S. B., & George, T. P. (2005) · The American Journal on Addictions · doi:10.1080/10550490590924728 · Cited by 594
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392
Pruessner, M., Cullen, A. E., Aas, M., & Walker, E. F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.013 · Cited by 315
Cited by
Taipale, H., Lähteenvuo, M., Tanskanen, A., Mittendorfer-Rutz, E., & Tiihonen, J. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa111 · Cited by 85
Baandrup, L. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13384 · Cited by 79
Rafizadeh, R., Danilewitz, M., Bousman, C. A., Mathew, N., White, R. F., Bahji, A., Honer, W. G., & Schütz, C. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221142575 · Cited by 41
“These dopaminergic pathways serve as the site of reward-based effects of addictive substances and are hypothesized to mediate motivation, pleasure, and contentment in daily life (Khokhar et al., 2017).”
BackgroundChiappini, S., Schifano, F., Corkery, J. M., & Guirguis, A. (2020) · Brain Sciences · doi:10.3390/brainsci10020105 · Cited by 33
Metadata
- Authors
- Khokhar, J. Y., Henricks, A. M., Sullivan, E. D. K., & Green, A. I.
- Venue
- Advances in Pharmacology
- Publisher
- Elsevier
- Published
- 2018
- Volume
- 82
- Pages
- 137-162
- ISSN
- 1054-3589 (ISSN-L)
- OpenAlex
- W2783247451
- Cited by
- 182
- References
- 13
- FWCI
- 73.84
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unique Effects of Clozapine: A Pharmacological Perspective. https://app.cochat.ai/papers/10.1016/bs.apha.2017.09.009
- The paper
- Khokhar, J. Y., Henricks, A. M., Sullivan, E. D. K., & Green, A. I. (2018). Unique Effects of Clozapine: A Pharmacological Perspective. Advances in Pharmacology. https://doi.org/10.1016/bs.apha.2017.09.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.